A pivotal, Phase 3 trial of MYK-461 in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Registrational; Therapeutic Use
- Sponsors MyoKardia
- 13 Dec 2017 According to a Sanofi media release, the company expects to initiate this study in 2018.
- 27 Jun 2017 New trial record
- 13 Mar 2017 According to a FORM 10-K of MyoKardia, overall duration of this trial will be approximately two years.